Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)

Inclusion criteria

• No prior treatment for cervical cancer.
• FIGO Stage IB1 to IVB; all histological subtypes (excluding neuro-endocrine type).
• Pelvic MRI available or planned before the start of treatment, , if FIGO ≥ IB2. and optional for IB1 stage
• Possibility to communicate imaging data by CD-ROM (format DICOM 3.0 or more).
• Disease amenable to biopsy (3 tumour samples are mandatory prior to treatment).
• Age ≥ 18 years.
• ECOG (Eastern Cooperative Oncology Group) 0-2.
• Life expectancy > 6 months.
• Patient eligible for standard treatment (according to standards of each center).
• Patient having health care insurance.
• Informed and signed consent by patient.

(DICOM = Digital Imaging and Communications in Medicine)

Exclusion criteria

• Patient enrolled in a clinical trial involving an investigative new agent.
• Co morbidity, preventing patient to tolerate the proposed standard treatment.
• Past history of invasive cancer over the 5 years preceding entry in the present trial (except basal cell carcinoma and carcinoma in situ of the cervix).
• Impossibility to carry out evaluation by MRI (patient claustrophobic, pacemaker, metallic implant, non availability, other), ), if FIGO ≥ IB2 .
• Patient deprived from ability to decide on her own.
• Patient unable to have a regular follow up for geographical, social or psychological reasons.
• Pregnancy or patient old enough to procreate and not using effective contraceptive method.